Bristol-Myers Squibb Company
Bispecific EGFR/IGFIR binding molecules

Last updated:

Abstract:

The present invention relates to bispecific molecules comprising an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins. Exemplary bispecific molecules include antibody-like protein dimers based on the tenth fibronectin type III domain.

Status:
Grant
Type:

Utility

Filling date:

30 Nov 2018

Issue date:

23 Mar 2021